Cerebrolysin

Cerebrolysin is a unique pharmaceutical preparation consisting of a standardized mixture of low-molecular-weight neuropeptides and free amino acids obtained from enzymatic breakdown of porcine (pig) brain proteins. Manufactured by EVER Neuro Pharma in Austria, it has been in clinical use since the 1970s and is approved as a medication in over 50 countries worldwide, though not in the United States.

The peptide mixture in Cerebrolysin has been shown to possess neurotrophic activity similar to naturally occurring nerve growth factors (NGF, BDNF, CNTF). These small peptides can cross the blood-brain barrier, which is significant because full-length neurotrophic proteins typically cannot. Once in the brain, Cerebrolysin appears to support neuronal survival, promote neurite outgrowth, enhance synaptic function, and modulate neuroinflammation.

Extensive clinical research has been conducted on Cerebrolysin, particularly for acute ischemic stroke, traumatic brain injury (TBI), and vascular and Alzheimer's dementia. The CASTA trial in stroke showed improved functional outcomes at 90 days when Cerebrolysin was added to standard care. Studies in Alzheimer's disease have shown improvements in cognitive function scales, though results have been variable across trials. Research in TBI has shown potential for neuroprotection and recovery enhancement.

While approved in many countries and backed by over 200 clinical studies, Cerebrolysin remains controversial in Western neurology. Critics point to heterogeneity in trial results, lack of FDA approval, and challenges in characterizing a complex biological mixture. Proponents emphasize the breadth of clinical evidence, its established safety record over decades of use, and the biological rationale for providing neurotrophic support to damaged or aging brains. The debate reflects broader tensions between pharmaceutical traditions in different regions.